

# Apolipoprotein A-I: the dual face of a protein

Angela Arciello<sup>1,2</sup>, Renata Piccoli<sup>1,2</sup> and Daria Maria Monti<sup>1,2</sup>

<sup>1</sup> Department of Chemical Sciences, University of Naples Federico II, Italy

<sup>2</sup> Istituto Nazionale di Biostrutture e Biosistemi (INBB), Rome, Italy

## Correspondence

D. M. Monti, Department of Chemical Sciences, University of Naples Federico II, Via Cinthia 4, 80126 Naples, Italy  
 Fax: +39 81 674199  
 Tel: +39 81 679150  
 E-mail: mdmonti@unina.it

(Received 2 August 2016, revised 12 October 2016, accepted 24 October 2016, available online 11 November 2016)

doi:10.1002/1873-3468.12468

Edited by Barry Halliwell

**Conformational plasticity and flexibility are key structural features of ApoAI in lipid metabolism. Amyloidogenic single point mutations, associated with incurable familial amyloidosis with fibril deposition in peripheral organs, may have a dramatic impact on the structural and functional features of ApoAI. Here, the consistent body of data on ApoAI variants has been reviewed, with the aim of highlighting the hallmarks of the pathology. In accordance with our observations, as well as that of others, we propose a model that accounts for the alteration of the delicate balance between lipid-free/lipid-bound dynamic states which is based on monomer-to-dimer interconversion *via* domain swapping.**

**Keywords:** aggregation; amyloidosis; Apolipoprotein A-I; conformational diseases; domain swapping; protein misfolding

## The natural protein and its physiological role

Apolipoprotein A-I (ApoAI) is synthesized mainly by the liver and the intestine as a preproprotein. After cleavage of the pre- and pro-peptides, the mature protein (28 kDa, 243 amino acids) is secreted in the plasma as a lipid-poor/lipid-free protein, which is the main acceptor of cholesterol from artery wall cells [1]. It has been demonstrated that ABCA1 mediates the secretion of cellular-free cholesterol and phospholipids to ApoAI, its extracellular acceptor, to form nascent high-density lipoproteins (HDLs) [2–4]. It emerged that HDLs are dynamic entities undergoing remodeling, lipolysis, and fusion that convert small particles to large particles and *vice versa* [4]. ApoAI is the principal component (about 70% of proteins) of HDL, nanoassemblies acting as carriers for cholesterol transfer, *via* the plasma, from the periphery to steroidogenic tissues, and to the liver for catabolism in the so called reverse cholesterol transport [5,6].

A delicate balance between the lipid associated (about 95%) and not associated (about 5%) state of

ApoAI accounts for its critical role as a lipid metabolism regulator [7] and as a modulator of atherosclerosis. Although the molecular mechanism of the atheroprotective action of ApoAI, as well as HDL biogenesis, is not fully understood, it is known that ApoAI plays an antiatherogenic action *in vivo*, with a protecting effect against cardiovascular diseases [8], since atherosclerosis of hypercholesterolemic mice lacking ApoAI [9,10] is counteracted by ApoAI transgenic expression [11,12].

Key structural features for ApoAI functions are conformational plasticity and flexibility, based on the presence of 10 tandem of 11/22 residue repeats (H1–H10) which form amphipathic lipid-binding  $\alpha$ -helices. Following the first crystal structure of lipid-free human ApoAI, truncated at the N terminus ( $\Delta$ 1–43) [13], a high-resolution (2.2 Å) crystal structure was obtained using a C-terminally truncated ( $\Delta$ 185–243) form of the protein [14] to facilitate crystallization, the C-terminal region being highly unfolded in solution. The structure provided evidence that ApoAI forms a half-circle dimer, in which two elongated antiparallel helices connect two–four-helix bundles (Fig. 1A), each

## Abbreviations

AApoAI, amyloidogenic variant of ApoAI; ANS, 8-anilino-1-naphthalensulfonic acid; ApoAI, Apolipoprotein A-I; CD, circular dichroism; DLS, dynamic light scattering; FAP, familial amyloidosis polyneuropathy; HDL, high-density lipoproteins; MD, molecular dynamics.

constituted by the N terminus of one chain (residues 1–121, helices I, II, III) and the C terminus of its partner (residues 143–184, helix IV). However, it has to be pointed out that the only high-resolution crystal structure so far available refers to a truncated form of the protein, and therefore could be different from the real solution form of the natural protein.

## ApoAI and amyloidogenicity

Apolipoprotein A-I can be the causative agent of acquired or familial amyloidoses. In the acquired, that is, not inherited amyloidosis, the deposition of wild-type full-length ApoAI occurs in arterial plaques (atherosclerosis) [15,16]. This has to be ascribed to the lower thermodynamic stability of lipid-free ApoAI with respect to the HDL-bound protein. It has also to be highlighted that oxidation of methionine residues of lipid-free ApoAI has been identified as a primary cause of protein destabilization and amyloid deposition in atherosclerotic plaques, where high levels of oxidized lipid-free ApoAI were detected [17,18].


The first analysis of amyloid deposit composition in localized forms of ApoAI-associated amyloidoses provided evidence of the presence of ApoAI-derived N-terminal fragments in aortic amyloid deposits [19]. In the knee joint menisci of patients with knee osteoarthritis, amyloid deposits were found to be mainly constituted by ApoAI produced *in situ* by chondrocytes [20].

Familial amyloidosis polyneuropathy (FAP), instead, is associated with mutations in APOA1 gene. About 20 natural mutations (Fig. 2) were mapped so far as responsible for ApoAI systemic amyloidoses. In patients carrying an amyloidogenic ApoAI variant (AApoAI), amyloid deposition occurs overtime in


peripheral organs, such as heart, liver, kidneys, skin, etc. [21].

No cure is available for these pathologies, being organ transplantation the only possible treatment. In AApoAI patients, ApoAI and HDL plasma levels are generally lower than in normal subjects [22,23], although this seems not to be the cause of cardiovascular diseases [24]. ApoAI-decreased plasma levels may be related to the lower amount of secreted amyloidogenic variants with respect to wild-type ApoAI, as demonstrated for L75P-AApoAI overexpressed in stably transfected human hepatic cells [25], as well as for L75P- and L174S-AApoAI variants in transiently transfected COS-7 cells [26].

The amyloidogenic mutations described so far in patients, all heterozygous for the mutated gene, can be divided in two groups: those located within the N-terminal portion of the protein that is found in fibrils ('inside mutations'), and those located externally to this region ('outside mutations') [23] (Fig. 2). Whenever an amyloidogenic mutation is located, internally or externally to the N-terminal region, amyloid fibrils isolated *ex vivo* were found to be mainly constituted by the N-terminal fragments of AApoAI, 80–100 residue long. For instance, G26R point mutation, the first amyloidogenic mutation discovered in ApoAI [27], enhances the formation of fibrils containing ApoAI fragment 1–83, whereas amyloid fibrils extracted from patients carrying the first AApoAI outside mutation identified (L174S) [28,29] were mainly constituted by fragment 1–93. We performed a comparative analysis of the aggregation propensity of eight recombinant isoforms of ApoAI 1–93 polypeptide, each carrying a known amyloidogenic mutation of the N-terminal region [30]. The data supported the hypothesis that 'inside' amyloidogenic mutations might enhance protein



**Fig. 1.** (A) Ribbon representation of the crystal structure of lipid-free  $\Delta$ 185–243 human ApoAI dimer (PDB code 3R2P). (B) A model proposed for the monomeric structure, as suggested by Mei and Atkinson [14].



**Fig. 2.** ApoAI mutations associated with systemic amyloidoses. In red, the mutations located within the N-terminal fibrillogenic region ('inside mutations'). In blue, the 'outside mutations'.  $\Delta$ , deletion mutations; fs, frameshift mutations.

flexibility in the proximity of the putative cleavage site releasing the N-terminal amyloidogenic domain [30], consistently with Lagerstedt *et al.* [31]. We also provided evidence that an increased aggregation propensity of isoforms of the N-terminal polypeptide is not causative *per se* of amyloidogenesis [30].

### Hallmarks of a pathogenic protein: impact of mutations on protein conformation

Nothing is known about the molecular mechanism responsible for the release *in vivo* of a fibrillogenic polypeptide from a full-length AApoAI variant, nor in which context it occurs. In such an uncertain scenario, any structural or functional difference between the natural protein and a pathological version of it would represent an important clue to reveal mechanistic aspects of the disease.

Interestingly, the majority of the amyloidogenic mutations identified so far cluster in two regions: the amino-terminus (residues 1–100) and within residues 170–178, which in ApoAI 3D structure are located in the four-helix bundle domain and define a 3D hot spot mutation site [14]. Based on sequence analyses, four hot spots, corresponding to regions 14–22, 53–58, 69–72, and 227–232, have been predicted [32]. Amyloidogenic mutations occurring in these regions were proposed to perturb the protein structure prompting aggregation *via* the N-terminal region [32]. With the exception of 53–58, these regions are mainly in  $\alpha$ -helical structure, with region 227–232 representing the primary lipid-binding site of the protein. Noticeable is that ApoAI fibrillogenic polypeptides (residues from 1 to 80–100) encompass all of the N-terminal predicted hot spots. To date, from the analysis of some of the naturally occurring full-length AApoAI variants identified so far, for example, G26R, W50R, F71Y, L75P, A164S, L170P, R173P, L174S, and L178H, interesting peculiarities of their conformational behavior have emerged.

Two hypotheses have been raised on the chronology of the events occurring during fibrillogenesis. In one case, ApoAI destabilization induced by amyloidogenic

mutations allows the cleavage of the full-length protein and the release of the fibrillogenic polypeptide with consequent aggregation in fibrils [23,29–31,33,34]. Alternatively, it has been hypothesized that destabilization of AApoAI four-helix bundle promotes aggregation of the full-length variant, an event that precedes the proteolytic cleavage releasing the N-terminal region [32].

The elucidation of any structural differences between AApoAI variants and the natural protein may be fundamental to elucidate molecular determinants that make a protein amyloidogenic. From the large body of data reported on amyloidogenic variant behavior with respect to natural ApoAI, a picture emerges indicating that the amyloidogenic phenotype is associated with altered structural features, which are reported below grouped into four main categories.

### Effects of mutations on protein conformation and lipid binding

Generally, amyloidogenic mutations induce protein disorder, as demonstrated by CD analyses. Variants F71Y-AApoAI and L170P-AApoAI showed a decreased CD signal at 185–200 nm [32]; similar effects, although much less evident, have been described for G26R and W50R mutations [32,35]; in the case of L75P-AApoAI and L174S-AApo-I, an increased percentage of  $\beta$ -sheet structure has been detected [36]; G26R, W50R, and F71Y mutations cause marked changes in near-UV CD, while L170P substitution is associated with the largest change with more negative CD signals at 255–280 nm. Moreover, studies by amide hydrogen–deuterium exchange demonstrated that the G26R mutation destabilizes the protein through the large region spanning residues 10–114, causing changes in protein structure and dynamics [37]. As a consequence, the N-terminal helix unfolds, inhibiting interactions within the N-terminal helix bundle, which is destabilized.

Which are the consequences of an altered conformation? One should consider that all the above mentioned residues contribute in the native protein to the

four-helix bundle stability. In particular, residue L75 is located in the middle of the four-helix bundle, within the short helix 70–76 that contributes to define the relative helical orientation in the bundle; G26 and W50 are also located in the middle of the bundle [38], whereas F71, L170, and L174 are located at the ‘bottom’ of it [32]. Therefore, it is conceivable that, associated with these mutations, and as a consequence of the altered conformation, hydrophobic regions are more exposed to the solvent than in the native protein, as it has been described for L75P-AApoAI and L174S-AApoAI, with a consequent increase in tryptophan and 8-anilino-1-naphthalensulfonic acid (ANS) fluorescence emission [36]. A slight increase in ANS emission was detected also for G26R-, W50R-, and F71Y-AApoAI [35]. On the other hand, for L170P-AApoAI a decrease in ANS emission was described, possibly due to an increased order in the C terminus, a potential ANS-binding site. This is in line with a significantly decreased deuteration of L170P-AApoAI in its C-terminal tail (see below).

Generally, mutations do not promote dissociation of the free protein from HDL [32], nor do they impair the protein ability to bind to model phospholipids generating HDL-like complexes of unaltered size. However, mutations may decrease the lipoprotein stability [35]. To this regard, G26R and W50R mutations slightly reduce protein ability to recruit lipids to form HDL [35], whereas larger destabilization occurs in the case of the ‘outside’ mutation L170P. Mutation L178H is responsible for an altered lipid-binding profile [39]; similarly, R173P-AApoAI shows lower efficiency to bind to phospholipid vesicles [40] and A164S-AApoAI has lower binding affinity to lipids [41].

### Effects of mutations on protein flexibility and stability

A generally decreased compactness is described for AApoAI variants. This is at least in part related to an increased flexibility of the protein chain, accompanied by a reduced stability and loss of unfolding cooperativity, as it has been observed for several AApoAI variants [32,35–37]. Importantly, it has been pointed out [35] that destabilization is not necessarily associated with misfolding, as demonstrated by some destabilized, but not amyloidogenic, variants (e.g., Milano variant) [42].

The DLS measurements of the hydrodynamic diameter indicated that L75P-AApoAI is much less compact than the wild-type protein and L174S-AApoAI. Upon 7 days of incubation at 37 °C, L75P-AApoAI

and L174S-AApoAI diameter increased by about 50% and 44%, respectively [14]. Mutation-driven protein destabilization occurs at different degrees, being less evident in case of G26R-AApoAI and W50R-AApoAI variants (–5 °C Tm), and more evident for L170P-AApoAI (–11 °C Tm), L174S-AApoAI (–12 °C Tm), and L75P-AApoAI (–14 °C Tm) [31,32,35,36].

Again, a direct relationship between destabilization and aggregation propensity cannot be envisaged. Hydrogen–deuterium exchange studies revealed that G26R mutation greatly increases solvent accessibility and dynamics at the N terminus (first 90 residues), as reported above [37]; L170P-AApoAI is less protected from exchange at the major hot spot 14–22 among the variants tested [35]. Mutations F71Y and W50R have little effects on the C-terminal deuteration, while mutation L170P induces a significant decrease in deuteration, probably due to a more extensive packing of the protein tail against the helix bundle, as reported above.

### Effects of mutations on susceptibility to proteases

It is conceivable that, as a direct consequence of the decreased compactness and increased flexibility, susceptibility to proteases increases.

Enhanced susceptibility to protease cleavage has been demonstrated in the N-terminal region of L75P-AApoAI and L174S-AApoAI [36], to be related to N-terminal destructure and disorder. Exposure of a proteolytic site at Y18, belonging to the major hot spot 14–22, was revealed in variants G26R-, L75P-, L174S-, and L178H-AApoAI [31,36,39], while, in the case of L174S-AApoAI, cleavages at R153 and Y166 occur, as expected from MD simulations experiments which indicated that region 153–166 is unstructured [36]. Similarly, in L75P-AApoAI the accessibility of proteolytic sites at E34 and F57 (the latter belonging to the minor hot spot 53–58), both hindered in the native protein, is the consequence of the propagation of a local perturbation (helix 70–76) to the other predicted hot spots and the cause of the decreased protein compactness.

Moreover, some mutations (e.g., L170P and G26R) cause a disorder in the  $\alpha$ -helical segment 83–93 by possibly exposing a proteolytic site that might be involved in the release of the N-terminal region, while other mutations (e.g., F71Y and W50R) do not [32]. Similarly, in L174S-AApoAI, the C terminus seems to be protected, as shown by the disappearance of the E223 cleavage site (exposed in the native protein and in L75P-AApoAI), as well as by slower hydrolysis kinetic at R188 and Y192 residues [36], thus suggesting that conformational changes occurred in this region.

### Effects of mutations on aggregation propensity

A time-dependent increase of the  $\beta$ -sheet structure in L75P-AApoAI and L174S-AApoAI has been reported [36], similarly to G26R-AApoAI [39], whereas for L178H-AApoAI an increase in the  $\alpha$ -helical content has been described over time, accompanied by the formation of very short fibrillar structures [39]. Beaded morphology of L75P-AApoAI fibrils well correlates with the lower protein compactness, whereas the more compact structure of L174S-AApoAI, combined with its high flexibility, is in agreement with the formation of thinner and longer fibrils.

### Common features of amyloidogenic mutations effects

A key feature of ApoAI is its conformational plasticity and flexibility that make possible a prompt adaptation of the protein to different environmental conditions. ApoAI is, therefore, an optimal flexible scaffold for lipidation/delipidation and cholesterol circulation, since, due to its molten globule state, the protein is able to easily switch from the presumed monomeric state in the absence of lipids (about 5% of total ApoAI) to an extended double belt-like conformation in the lipid-bound state, with antiparallel  $\alpha$ -helices wrapped around the edge of nascent HDL. On the other hand, the high protein flexibility is a key element involved in pathological conditions, when an amyloidogenic mutation alters the protein architecture, switching the dynamic state of the native protein toward a 'pathology-competent state'.

A wide range of effects can be ascribed to point mutations. From a general point of view, the effects of mutations can be summarized here as follows: (a) induction of protein disorder with loss of protein compactness; (b) destabilization of the N-terminal helix bundle; (c) exposure of hydrophobic regions to the solvent; (d) increase in protein flexibility and consequent susceptibility to proteases; (f) altered lipid-binding profile.

The model recently proposed by Das *et al.* [32] prompts that AApoAI amyloidogenic mutations perturb one of the four predicted hot spots of the protein (14–22, 53–58, 69–72, and 227–232), with a consequent full-length protein aggregation *via* the N-terminal region. In particular, mutation-driven perturbations of the native structure would allow the exposure of the major amyloid hot spot 14–22, normally buried in the middle of the four-helix bundle, triggering protein misfolding and aggregation. Thus, the paradigm proposed is the following: conformational perturbation—exposure of hot spots—protein aggregation.

However, some further considerations may be added. First, a question can be raised: from the data available so far on AApoAI variants can a more general rule be drawn to classify the effects of mutations on protein misfolding? To this regard, on the basis of experimental evidence, it is tempting to propose that 'inside' and 'outside' mutations have a different impact on the protein, with internal mutations destabilizing preferentially the N-terminal region, and significantly altering protein conformation and compactness, while external mutations, besides determining N-terminal destabilization, increase the overall protein flexibility and induce a more pronounced aggregation-competent state. As prototypes of internal and external mutations, respectively, L75P-AApoAI is less compact, while L174S-AApoAI is more flexible. In the natural protein, the flexible C-terminal tail has low protection as it interacts weakly with the helix bundle. In the presence of external mutations (mainly clustered in the region 170–178), the C-terminal tail is more protected and less exposed, as demonstrated by L170P-AApoAI lower deuteration kinetics, as well as by L174S-AApoAI and L178H-AApoAI lower susceptibility of this region to proteases with respect to the natural protein. Based on the observation that L170P mutation greatly reduces protection from hydrogen–deuterium exchange in the 83–93 region [32], it has been hypothesized that an increased disorder in the well-ordered  $\alpha$ -helical segment 83–93 may facilitate proteolytic cleavage(s) in AApoAI variants.


A second consideration emerges from the model proposed by Das *et al.* [32], suggesting that a mutated protein is *per se* endowed with special molecular features that make it amyloidogenic. At the same time, intriguing but fully unexplained so far is the observation that for some AApoAI variants a preferential fibril deposition in certain tissues occurs. As an example, variant L75P-AApoAI is associated with a hereditary systemic amyloidosis characterized by preferential accumulation of fibrils in kidneys and liver [43]. Instead, in the case of L174S-AApoAI, a predominant accumulation of fibrils in heart, skin, testes, and larynx was observed [21]. The molecular bases of the differential localization of amyloid fibrils are still unknown. Different environments (e.g., composition of cell membrane, extracellular matrix, soluble molecules) might promote the unfolding/aggregation pathway of a particular variant. If so, the physiological context would be crucial and might play a key role to determine the still unclear phenomenon of tissue specificity of fibril deposition described for some variants.

## A possible model

It has been proposed that, following binding to lipids, ApoAI dimerization occurs *via* the opening of the N-terminal four-helix bundle and the displacement of the C-terminal region toward a second monomer and *vice versa* to form an antiparallel helical ‘double belt’ on the HDL surface [14,44–46].

As monomers are metastable, they might switch from a nonswapped to a swapped conformation, with consequent dimerization, so that domain swapping could be a natural consequence of the metastability of the interconverting species. It is tempting to speculate that such a flexible, aggregation prone protein, as it is wild-type ApoAI, may escape aggregation *via* lipid binding, which would promote dimer formation through domain swapping.

In the model we propose (Scheme 1), lipids facilitate monomer-to-dimer conversion, while AApoAI mutations, perturbing the natural protein conformation (dotted line structure in Scheme 1), alter its propensity to dimerize, modifying consequently the physiologic dynamic equilibrium between the interconverting species. In case of an altered equilibrium between lipid-bound and lipid-free ApoAI, not efficiently balanced by ApoAI lipid-free clearance, the risk of aggregation would dramatically increase. Indeed, studies on a recombinant N-terminal fibrillogenic polypeptide (residues 1–93) demonstrated the effects of cholesterol, as well as of zwitterionic, positively and negatively charged liposomes in trapping the polypeptide in a helical state, preserving it from aggregation [47]. A similar effect of the lipid environment has also been described for other amyloidogenic proteins, for



**Scheme 1.** Schematic representation of the monomeric and dimeric state of ApoAI. The conversion from monomer to dimer is facilitated by lipid binding and achieved by domain swapping of the C-terminal tails between two ApoAI chains. Amyloidogenic mutations alter structural and functional parameters of the protein, deviating the monomer-to-dimer balance toward unstable forms of the monomer prone to aggregation. We hypothesize that a key factor responsible for tissue-specific deposition of ApoAI amyloidogenic variants is their interaction with cell membrane and/or extracellular (ECM) matrix components.

example, for  $\alpha$ -synuclein, a protein with an apolipoprotein lipid-binding motif [48].

To accomplish domain swapping, the C-terminal region of a monomer has to displace from its initial position and to shift toward the partner molecule by breaking the intramolecular interactions within the four-helix bundle and the reestablishing of similar contacts with the N-terminal  $\alpha$ -helices belonging to the partner molecule. A lower exposition of the C-terminal region to the solvent, as it has been found for L170P-, L174S-, and L178H-AApoAI, could impair protein interaction with lipids, and/or the C-terminal displacement required for domain swapping, that is, it could impair monomer-to-dimer conversion.

The alteration of protein conformation due to amyloidogenic mutations is able to propagate to the far sites of the protein *via* the central hinge region (repeat H5) that allows the interconversion between the monomer and dimer. Therefore, a potentially key element is expected to be the structural organization of the central linker 121–142, and possibly its flanking regions, which is highly flexible and probably facilitates the domain swapping of helix IV (residues 143–184) of the four-helix bundle during monomer-to-dimer conversion. In this regard, partial exposure to proteases of L75P-AApoAI at residue K96, and of L174S-AApoAI at residue Y115 [36], as well as the destabilization of region 81–115 in AApoAI-G26R, which allows proteolysis at residue 83 *in vivo* and consequent release of a fibrillogenic polypeptide [34,37], could be clues of the altered propensity to undergo monomer-to-dimer conversion. Dynamic simulation studies on the nonamyloidogenic ApoAI variants, Milano and Paris [49], in which an arginine residue at position 173 and 151, respectively, is mutated into a cysteine, suggest that in the lipid-bound protein the two antiparallel strands of the central linker undergo reorganization by a rotationally circular motion of the two monomers to find proper registration, thus supporting the intrinsic protein flexibility.

We hypothesize that in a cellular environment the interactions of the protein with lipids may play a critical role in impeding, or in slowing down, the fibrillogenic process by entrapping the protein in a stable helical structure unable to aggregate. Therefore, the occurrence of 3D-domain swapping seems to have a physiological significance. Membrane and extracellular matrix components may regulate this interconversion, altering the balance between aggregated and unaggregated states of the protein. The impact of a different membrane and/or extracellular matrix composition in different tissues on protein aggregation evokes the fascinating hypothesis that the combination of a particular conformational state (conformer) of the protein, as

well as its interaction with a particular class of lipids, may be key elements to explain the tissue-specific deposition observed for ApoAI amyloidogenic isoforms.

In this scenario, the destabilization of protein hot spots, although a central element for the comprehension of ApoAI amyloidogenesis, would be a condition certainly necessary, but not *per se* sufficient to trigger amyloidosis, as the recognition of specific molecules (possibly lipids) on different cell types and in different cell contexts could be decisive to make particular cell types the natural target for the development of the pathology.

## Acknowledgements

The authors thank Prof. Antonello Merlino for helpful discussion and Fig. 1 preparation.

## Author contributions

All authors conceived and wrote the review.

## References

- 1 Kane JP and Mallott MJ (2012) Pre $\beta$ -1 HDL and coronary heart disease. *Curr Opin Lipidol* **23**, 367–371.
- 2 Panagotopoulos SE, Horace EM, Maiorano JN and Davidson WS (2001) Apolipoprotein A-I adopts a belt-like orientation in reconstituted high density lipoproteins. *J Biol Chem* **276**, 42965–42970.
- 3 Li HH, Lyles DS, Pan W, Alexander E, Thomas MJ and Sorci-Thomas MG (2002) ApoA-I structure on discs and spheres. Variable helix registry and conformational states. *J Biol Chem* **277**, 39093–39101.
- 4 Wang S and Smith JD (2014) ABCA1 and nascent HDL biogenesis. *BioFactors* **40**, 547–554.
- 5 Curtiss LK, Valenta DT, Hime NJ and Rye KA (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? *Arterioscler Thromb Vasc Biol* **26**, 12–19.
- 6 Cavigiolio G, Geier EG, Shao B, Heinecke JW and Oda MN (2010) Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. *J Biol Chem* **285**, 18847–18857.
- 7 Fielding CJ and Fielding PE (1995) Molecular physiology of reverse cholesterol transport. *Lipid Res* **36**, 211–228.
- 8 Pastore L, Belalcazar LM, Oka K, Cela R, Lee B, Chan L and Beaudet AL (2004) Helper dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. *Gene* **327**, 153–160.

- 9 Rubin EM, Krauss RM, Spangler EA, Verstuyft JG and Clift SM (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. *Nature* **353**, 265–267.
- 10 Voyiakiakis E, Goldberg IJ, Plump AS, Rubin EM, Breslow JL and Huang LS (1998) ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. *J Lipid Res* **39**, 313–321.
- 11 Liu AC, Lawn RM, Verstuyft JG and Rubin EM (1994) Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. *J Lipid Res* **35**, 2263–2267.
- 12 Plump AS, Scott CJ and Breslow JL (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. *Proc Natl Acad Sci USA* **91**, 9607–9611.
- 13 Borhani DW, Rogers DP, Engler JA and Brouillette CG (1997) Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. *Proc Natl Acad Sci USA* **94**, 12291–12296.
- 14 Mei X and Atkinson D (2011) Crystal structure of C-terminal truncated apolipoprotein A-I reveals the assembly of HDL by dimerization. *J Biol Chem* **286**, 38570–38582.
- 15 Howlett GJ and Moore KJ (2006) Untangling the role of amyloid in atherosclerosis. *Curr Opin Lipidol* **17**, 541–547.
- 16 Ramella NA, Rimoldi OJ, Prieto ED, Schinella GR, Sanchez SA, Jaureguiberry MS, Vela ME, Ferreira ST and Tricerri MA (2011) Human apolipoprotein A-I-derived amyloid: its association with atherosclerosis. *PLoS One* **6**, e22532.
- 17 Wong YQ, Binger GJ, Howlett GJ and Griffin MD (2010) Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I. *Proc Natl Acad Sci USA* **107**, 1977–1982. 43.
- 18 Chan GK, Witkowski A, Gantz DL, Zhang TO, Zanni MT, Jayaraman S and Cavigiolio G (2015) Myeloperoxidase-mediated methionine oxidation promotes an amyloidogenic outcome for Apolipoprotein A-I. *J Biol Chem* **290**, 10958–10971.
- 19 Westermark P, Mucchiano G, Marthin T, Johnson KH and Sletten K (1995) Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. *Am J Pathol* **147**, 1186–1192.
- 20 Yanagisawa A, Ueda M, Sueyoshi T, Nakamura E, Tasaki M, Suenaga G, Motokawa H, Toyoshima R, Kinoshita Y, Misumi Y *et al.* (2016) Knee osteoarthritis associated with different kinds of amyloid deposits and the impact of aging on type of amyloid. *Amyloid* **23**, 26–32.
- 21 Mangione P, Sunde M, Giorgetti S, Stoppini M, Esposito G, Gianelli L, Obici L, Asti L, Andreola A, Viglino P *et al.* (2001) Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. *Protein Sci* **10**, 187–199.
- 22 Sorci-Thomas M and Thomas MJ (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. *Trends Cardiovasc Med* **12**, 121–128.
- 23 Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G and Bellotti V (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. *Amyloid* **13**, 1–15.
- 24 Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT *et al.* (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. *Am J Pathol* **179**, 1978–1987.
- 25 Del Giudice R, Monti DM, Sarcinelli C, Arciello A, Piccoli R and Hu GF (2014) Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin. *Cell Death Dis* **5**, e109715.
- 26 Marchesi M, Parolini C, Valetti C, Mangione P, Obici L, Giorgetti S, Raimondi S, Donadei S, Gregorini G, Merlini G *et al.* (2011) The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. *Biochim Biophys Acta* **1812**, 87–93.
- 27 Nichols WC, Dwulet FE, Liepnieks J and Benson MD (1988) Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. *Biochem Biophys Res Commun* **156**, 762–768.
- 28 Obici L, Bellotti V, Mangione P, Stoppini M, Arbustini E, Verga L, Zorzoli I, Anesi E, Zanotti G, Campana C *et al.* (1999) The new apolipoprotein A-I variant Leu (174) to Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. *Am J Pathol* **155**, 695–702.
- 29 Andreola A, Bellotti V, Giorgetti S, Mangione P, Obici L, Stoppini M, Torres J, Monzani E, Merlini G and Sunde M (2003) Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. *J Biol Chem* **278**, 2444–2451.
- 30 Raimondi S, Guglielmi F, Giorgetti S, Di Gaetano S, Arciello A, Monti DM, Relini A, Nichino D, Doglia SM, Natalello A *et al.* (2011) Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. *J Mol Biol* **407**, 465–476.
- 31 Lagerstedt JO, Cavigiolio G, Roberts LM, Hong HS, Jin LW, Fitzgerald PG, Oda NM and Voss JC (2007)



- Mapping the structural transition in an amyloidogenic apolipoprotein A-I. *Biochemistry* **46**, 9693–9699.
- 32 Das M, Mei X, Jayaraman S, Atkinson D and Gursky O (2014) Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing- a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis. *FEBS J* **281**, 2525–2542.
- 33 Arciello A, De Marco N, Del Giudice R, Guglielmi F, Pucci P, Relini A and Monti DM (2011) Piccoli R Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells. *J Cell Mol Med* **15**, 2652–2663.
- 34 Adachi E, Nakajima H, Mizuguchi C, Dhanasekaran P, Kawashima H, Nagao K, Akaji K, Lund-Katz S, Phillips MC and Saito H (2013) Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation. *J Biol Chem* **288**, 2848–2856.
- 35 Das M, Wilson CJ, Mei X, Wales TE, Engen JR and Gursky O (2016) Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: What makes the protein amyloidogenic? *J Mol Biol* **428**, 449–462.
- 36 Del Giudice R, Arciello A, Itri F, Merlino A, Monti M, Buonanno M, Penco A, Canetti D, Petruk G, Monti SM *et al.* (2016) Protein conformational perturbations in hereditary amyloidosis: differential impact of single point mutations in ApoAI amyloidogenic variants. *Biochim Biophys Acta* **1860**, 434–444.
- 37 Chetty PS, Ohshiro M, Saito H, Dhanasekaran P, Lund-Katz S, Mayne L, Englander W and Phillips MC (2012) Effects of the Iowa and Milano mutations on apolipoprotein A-I structure and dynamics determined by hydrogen exchange and mass spectrometry. *Biochemistry* **51**, 8993–9001.
- 38 Gursky O, Mei X and Atkinson D (2012) The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. *Biochemistry* **51**, 10–18.
- 39 Petrlova J, Duong T, Cochran MC, Axelsson A, Mörgelin M, Roberts LM and Lagerstedt JO (2012) The fibrillogenic L178H variant of apolipoprotein A-I forms helical fibrils. *J Lipid Res* **53**, 390–398.
- 40 Rosú SA, Rimoldi OJ, Prieto ED, Curto LM, Delfino JM, Ramella NA and Tricerri MA (2015) Amyloidogenic propensity of a natural variant of human apolipoprotein a-I: stability and interaction with ligands. *PLoS One* **10**, e0124946.
- 41 Dalla-Riva J, Lagerstedt JO and Petrlova J (2015) Structural and functional analysis of the apolipoproteina-I A164S variant. *PLoS One* **10**, e0143915.
- 42 Alexander ET, Tanaka M, Kono M, Saito H, Rader DJ and Phillips MC (2009) Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I. *J Lipid Res* **50**, 1409–1419.
- 43 Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, Arbustini E, Verga L, Marciano S, Donadei S, Perfetti V *et al.* (2004) Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. *Gastroenterology* **126**, 1416–1422.
- 44 Segrest JP, Jones MK, Shao B and Heinecke JW (2014) An experimentally robust model of monomeric apolipoprotein AI created from a chimera of two X-ray structures and molecular dynamics simulations. *Biochemistry* **53**, 7625–7640.
- 45 Brouillette CG, Anantharamaiah GM, Engler JA and Borhani DW (2001) Structural models of human apolipoprotein A-I: a critical analysis and review. *Biochim Biophys Acta* **1531**, 4–46.
- 46 Mei X and Atkinson D (2015) Lipid-free apolipoprotein AI structure: insights into HDL formation and atherosclerosis development. *Arch Medic Res* **46**, 351–360.
- 47 Monti DM, Guglielmi F, Monti M, Cozzolino F, Torrassa S, Relini A, Pucci P, Arciello A and Piccoli R (2010) Effects of a lipid environment on the fibrillogenic pathway of the N-terminal polypeptide of human apolipoprotein A-I, responsible for in vivo amyloid fibril formation. *Eur Biophys J* **39**, 1289–1299.
- 48 Zhu M and Fink AL (2003) Lipid binding inhibits  $\alpha$ -synuclein fibril formation. *J Biol Chem* **278**, 16873–16877.
- 49 Caulfield TR (2011) Inter-ring rotation of apolipoprotein A-I protein monomers for the double-belt model using biased molecular dynamics. *J Mol Graph Model* **29**, 1006–1014.